The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis
- Equal contributors
1 Department of Nephrology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
2 Institute of Immunology of PLA, Third Military Medical University, Chongqing 400038, China
3 Department of Immunology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba R3E 0 T5, Canada
Arthritis Research & Therapy 2013, 15:R161 doi:10.1186/ar4344Published: 24 October 2013
Additional file 1: Figure S1:
Showing the levels of serum LL-37 and IFNα before and after treatment. Serum levels of LL37 (A) and IFNα (B) were significantly decreased after immunosuppressive therapy than before treatment (n = 7, *P < 0.05).
Format: TIFF Size: 860KB Download file
Additional file 2: Figure S2:
Showing expression of MPO, LL37, IFNα and BDCA2 in AAV patients with crescentic GN. (A) Representative images showing the co-localisation of MPO (green) and LL37 (red) in the glomeruli of frozen renal biopsy sections after immunofluorescence staining. (B) Co-localisation of MPO (green) and IFNα (red) in renal biopsy sections from AAV patients with crescentic GN. (C) Co-localisation of MPO (green) and BDCA2 (red) in renal biopsy sections from AAV patients without crescentic GN.
Format: TIFF Size: 12.9MB Download file
Additional file 3: Figure S3:
Showing IFNα released from pDC. None IFNα were detected in the supernatants from neutrophils treated with or without anti-LAMP-2 antibodies (H4B4) for 3 hours. The mean level in the supernatants of IFNα was 7,357 pg/ml from pDCs incubated with ODN2216 groups, and was 866 pg/ml from pDCs incubated with supernatants of anti-LAMP-2 antibody-treated neutrophils. The level was under-detectible in supernatants from pDCs treated with medium.
Format: TIFF Size: 689KB Download file